Quarterly ResultAug 5, 2026, 06:37 AM
Recursion Q2 Net Loss Improves to $(131.0)M; Revenue Down to $7.67M
AI Summary
Recursion Pharmaceuticals reported a net loss of $(131.0) million for the second quarter of 2026, an improvement compared to $(171.9) million in the same period last year. However, total revenue significantly decreased to $7.67 million from $19.22 million year-over-year. The company's cash and cash equivalents were $545.68 million as of June 30, 2026, and it expects existing cash to fund operations for at least the next 12 months. Key operational updates include the acquisition of RE Ventures I and the sale of Exscientia GmbH.
Key Highlights
- Net loss for Q2 2026 was $(131.0) million, an improvement from $(171.9) million in Q2 2025.
- Total revenue for Q2 2026 decreased to $7.67 million from $19.22 million in Q2 2025.
- Net loss per share for Q2 2026 improved to $(0.25) from $(0.41) in Q2 2025.
- Cash and cash equivalents stood at $545.68 million as of June 30, 2026, down from $743.29 million at year-end 2025.
- Net cash used in operating activities for H1 2026 was $(187.05) million, an improvement from $(208.38) million in H1 2025.
- Accumulated deficit reached $(2.32) billion as of June 30, 2026.
- The company acquired Rallybio's interest in RE Ventures I for $20.2 million in July 2025.
- Recursion sold its Austrian operations (Exscientia GmbH) in March 2025, obtaining a 49% equity interest in Alpha Biotechnology GmbH.
Price Impact
More from RXRX